Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.

Authors:
Oldan JD; Giglio BC; Smith E; Zhao W; Bouchard DM and 18 more

Journal:
Oncoimmunology

Publication Year: 2023

DOI:
10.1080/2162402X.2023.2204753

PMCID:
PMC10142396

PMID:
37123046

Journal Information

Full Title: Oncoimmunology

Abbreviation: Oncoimmunology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement Funding for the LCCC1531 trial was provided by Merck & Co., Inc."

Evidence found in paper:

"Disclosure statement: Funding for the LCCC1531 trial was provided by Merck & Co., Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025